March 9. [9 am - 4 pm] |
Session 3: |
Probing the human (epi)genome for therapeutic opportunities
Hosted by Princess Margaret Cancer Centre, Chaired by Brad Wouters,
Executive VP Science and Research, University Health Network |
|
9:00-9:25 am |
Regulation of Endogenous Retroelements as an
Emerging Vulnerability and Therapeutic Opportunity
in Cancer Treatment and Interception |
Daniel De Carvalho,
Princess Margaret Cancer
Centre |
9:25-9:50 am |
Targeting epigenetic regulation in clear cell
renal cell carcinoma reveals PRMT1 as a novel
target |
Joe Walton, Princess
Margaret Cancer Centre |
9:50-10:05 am |
Abstract talk: Investigation of the role of the
epigenetic regulator, protein arginine methyltransferase 3 (PRMT3),
in cancer stem cell populations
|
Ravinder K Bahia,,
Department of Cell Biology and Anatomy,,
University of Calgary |
10:05-10:20 am |
Abstract talk: Suppressing cancer stem cell functions
in colon tumors by antagonizing dopamine transporter
|
Yannick D. Benoit,
Department of Cellular and Molecular Medicine,
University of Ottawa |
10:20 - 10:50 am |
Coffee Break |
Session 4: |
New tools for targeted protein degradation
Chaired by Sujata Sharma, Director, Structural & Protein Sciences, Janssen R&D |
10:50-11:15 am |
Interrogation of the GID4 interactome with PFI-7 |
Dominic Owens, SGC-Toronto,
Department of Pharmacology & Toxicology,
University of Toronto
|
11:15-11:40 am |
A novel E3 handle for degradation of NSD2 |
David Nie,
Princess Margaret Cancer Centre,
SGC-Toronto |
11:40-11:55 am |
Abstract talk: DCAF12: a new addition to the repertoire of
ubiquitin ligases for Targeted Protein Degradation
|
Germanna Righetto, SGC-Toronto,
Department of Pharmacology & Toxicology,
University of Toronto |
11:55 am -12:10 pm |
Abstract talk: PROTAC Virtual Screening Benchmark
|
Evianne Rovers, SGC-Toronto,
Department of Pharmacology & Toxicology,
University of Toronto |
12:10 - 13:10 pm |
Lunch Break |
Session 5: |
Initiatives to accelerate drug discovery and enhance data reproducibility
Chaired by Anke Mueller-Fahrnow, Chair of the Board of SGC |
1:10-1:35 pm |
The Chemical Probes Portal, a free, public online
resource of expert reviews and evaluations of
chemical probes |
Susanne Mueller-Knapp, SGC-Frankfurt,
Goethe University Frankfurt |
1:35-1:50 pm |
CACHE: setting the stage for a breakthrough in
computational hit finding |
Matthieu Schapira, SGC-Toronto
Department of Pharmacology & Toxicology,
University of Toronto |
1:50-2:15 pm |
YCharOS: Antibody characterization through open
science |
Peter McPherson, SGC-Neuro,
McGill University & YCharOS |
2:15-2:30 pm |
Abstract talk: Scalable Generation of Predictive
Binding Models Based on DEL Screening Data
|
Matthew Clark,
X-Chem Inc. |
2:30 - 3:00 pm |
Coffee Break |
|
Session 6: |
Looking toward the Future: Industry partnerships to support drug discovery
Hosted by Ontario Genomics, Chaired by Bettina Hamelin, President and CEO |
|
3:00-3:25 pm |
Target 2035: WDR proteins as a technology test-bed
for illuminating the dark proteome |
Levon Halabelian, SGC-Toronto,
Department of Pharmacology & Toxicology,
University of Toronto |
3:25-3:50 pm |
SGC-Promega collaborations: Co-developing novel
reagents for target engagement in cells |
Matt Robers, Promega |
3:50-4:00 pm |
Looking to the future: SGC and Target 2035 |
Aled Edwards, SGC CEO,
Department of Molecular Genetics,
University of Toronto |